NCT06186622View on ClinicalTrials.gov

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

January 2, 2024

Primary Completion Date

July 10, 2024

Study Completion Date

July 10, 2024

Conditions

HealthyObeseOverweight

Interventions

DRUG

Orforglipron

Administered orally.

DRUG

Simvastatin

Administered orally.

DRUG

Digoxin

Administered orally.

DRUG

Rosuvastatin

Administered orally.

DRUG

Acetaminophen

Administered orally.

DRUG

Midazolam

Administered orally.

DRUG

Sodium Bicarbonate

Administered orally.

Trial Locations (2)

32117

Fortrea Clinical Research Unit Inc., Daytona Beach

75247

Fortrea Clinical Research Unit Inc., Dallas

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06186622 - A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants | Biotech Hunter | Biotech Hunter